Rhythm Pharmaceuticals, Inc. (RYTM)

102.74 -2.15 (-2.05%) USD  |  NASDAQ  |  Sep 04, 16:00
102.77 +0.03 (+0.03%) After-Hours: 20:00
More

Rhythm Pharmaceuticals SG&A Expense (TTM) : 240.94M for June 30, 2026

SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for RYTM.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical SG&A Expense (TTM) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 240.94M
March 31, 2026 219.44M
December 31, 2025 194.94M
September 30, 2025 175.59M
June 30, 2025 158.54M
March 31, 2025 149.01M
December 31, 2024 144.30M
September 30, 2024 138.55M
June 30, 2024 133.65M
March 31, 2024 127.28M
December 31, 2023 117.53M
September 30, 2023 111.47M
June 30, 2023 102.94M
March 31, 2023 95.22M
December 31, 2022 92.03M
September 30, 2022 86.71M
June 30, 2022 82.28M
March 31, 2022 75.42M
December 31, 2021 68.49M
September 30, 2021 60.61M
June 30, 2021 54.39M
March 31, 2021 47.85M
December 31, 2020 46.12M
September 30, 2020 42.42M
June 30, 2020 41.67M
Date Value
March 31, 2020 41.59M
December 31, 2019 36.55M
September 30, 2019 35.52M
June 30, 2019 33.53M
March 31, 2019 31.12M
December 31, 2018 28.08M
September 30, 2018 24.02M
June 30, 2018 17.80M
March 31, 2018 12.72M
December 31, 2017 9.518M
September 30, 2017 5.188M
June 30, 2017 3.986M
March 31, 2017 4.101M
September 30, 2016 4.61M
June 30, 2016 5.532M
March 31, 2016 4.562M
December 31, 2015 3.397M
September 30, 2015 2.313M
December 31, 2014 1.953M
September 30, 2014 2.857M
June 30, 2014 3.256M
March 31, 2014 2.315M
June 30, 2013 1.753M
March 31, 2013 0.706M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 620.29M
Alnylam Pharmaceuticals, Inc. 1.318B
BioMarin Pharmaceutical, Inc. 1.368B
Cytokinetics, Inc. 370.47M
Exelixis, Inc. 533.92M